RXRecursion Pharmaceuticals RXRX · NASDAQ
$3.74 -2.60% (-$0.10)
- Market cap
- $1.96B
- Enterprise value
- $1.48B
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 35.8x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -48.3%
- Gross margin
- -46.7%
- Net margin
- -945.9%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 1.03
- Free float
- 77.9%
About the company
Recursion Pharmaceuticals is a biotechnology company that utilizes modern technologies such as artificial intelligence and machine learning to discover new therapeutic compounds and potential treatment approaches.
The key element of their approach is the use of image processing and data analysis systems to create comprehensive maps of cellular processes. This aims to identify potential targets for drugs and therapeutic substances in the fields of genetics, cellular biology, and diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Najat Khan
Employees
600
Headquarters
Salt Lake City
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number